These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15845909)

  • 1. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Hama S; Hough G; Reddy ST; Frank JS; Garber DW; Handattu S; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1426-32. PubMed ID: 15845909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Wagner AC; Hama S; Hough G; Bachini E; Garber DW; Mishra VK; Palgunachari MN; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1932-7. PubMed ID: 15961700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
    Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice.
    Navab M; Hama S; Hough G; Fogelman AM
    Circulation; 2003 Oct; 108(14):1735-9. PubMed ID: 14504179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.
    Nayyar G; Garber DW; Palgunachari MN; Monroe CE; Keenum TD; Handattu SP; Mishra VK; Anantharamaiah GM
    Atherosclerosis; 2012 Oct; 224(2):326-31. PubMed ID: 22771190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids.
    Navab M; Ruchala P; Waring AJ; Lehrer RI; Hama S; Hough G; Palgunachari MN; Anantharamaiah GM; Fogelman AM
    J Lipid Res; 2009 Aug; 50(8):1538-47. PubMed ID: 19225094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse D4F, an apolipoprotein-AI mimetic peptide, inhibits atherosclerosis in ApoE-null mice.
    Qin S; Kamanna VS; Lai JH; Liu T; Ganji SH; Zhang L; Bachovchin WW; Kashyap ML
    J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):334-43. PubMed ID: 22308547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential clinical utility of high-density lipoprotein-mimetic peptides.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
    Curr Opin Lipidol; 2006 Aug; 17(4):440-4. PubMed ID: 16832169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein A-I protection against atherosclerosis is dependent on genetic background.
    Sontag TJ; Krishack PA; Lukens JR; Bhanvadia CV; Getz GS; Reardon CA
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):262-9. PubMed ID: 24334873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein-E deficient mice.
    Pedersen TX; Bro S; Andersen MH; Etzerodt M; Jauhiainen M; Moestrup S; Nielsen LB
    Atherosclerosis; 2009 Feb; 202(2):372-81. PubMed ID: 18489910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein A-I mimetic peptides.
    Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Yu N; Ansell BJ; Datta G; Garber DW; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1325-31. PubMed ID: 15831812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.
    Woo JM; Lin Z; Navab M; Van Dyck C; Trejo-Lopez Y; Woo KM; Li H; Castellani LW; Wang X; Iikuni N; Rullo OJ; Wu H; La Cava A; Fogelman AM; Lusis AJ; Tsao BP
    Arthritis Res Ther; 2010; 12(3):R93. PubMed ID: 20482780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Processes involved in the site-specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice.
    Choy K; Beck K; Png FY; Wu BJ; Leichtweis SB; Thomas SR; Hou JY; Croft KD; Mori TA; Stocker R
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1684-90. PubMed ID: 15961704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum amyloid A and lipoprotein retention in murine models of atherosclerosis.
    O'Brien KD; McDonald TO; Kunjathoor V; Eng K; Knopp EA; Lewis K; Lopez R; Kirk EA; Chait A; Wight TN; deBeer FC; LeBoeuf RC
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):785-90. PubMed ID: 15692094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis.
    Charles-Schoeman C; Banquerigo ML; Hama S; Navab M; Park GS; Van Lenten BJ; Wagner AC; Fogelman AM; Brahn E
    Clin Immunol; 2008 May; 127(2):234-44. PubMed ID: 18337176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice.
    van der Hoorn JW; Kleemann R; Havekes LM; Kooistra T; Princen HM; Jukema JW
    J Hypertens; 2007 Dec; 25(12):2454-62. PubMed ID: 17984667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention.
    Navab M; Anantharamaiah GM; Reddy ST; Fogelman AM
    Nat Clin Pract Cardiovasc Med; 2006 Oct; 3(10):540-7. PubMed ID: 16990839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
    Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
    J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates.
    Kitamoto S; Nakano K; Hirouchi Y; Kohjimoto Y; Kitajima S; Usui M; Inoue S; Egashira K
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1522-8. PubMed ID: 15178560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.